Floatz logo

288 assets in Lymphoma

Therapeutic assets addressing Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
[18F]F-RESCA-RD06
Lymphoma
RenJi HospitalP2CCC (48)
[68ga]ga-nota-r8b4
Lymphoma
RenJi HospitalP2CCC (48)
[68ga]ga-nota-rd06
Lymphoma
RenJi HospitalP2CCC (48)
Allo-Quadcar01-T
Lymphoma
AvenCell Therapeutics, Inc.P1/2CCC (48)
Anti-Cd20/Cd3 Monoclonal Antibody Regn1979
Lymphoma
Gottfried von Keudell, MD PhDP2CCC (48)
Balstilimab
Lymphoma
Immune Oncology Research InstituteP2CCC (48)
Brincidofovir
Lymphoma
SymBio PharmaceuticalsP1/2CCC (48)
Eflapegrastim
Lymphoma
Spectrum Pharmaceuticals, IncP2CCC (48)
Elimusertib
Lymphoma
National Cancer Institute (NCI)P1/2CCC (48)
Eltrombopag
Lymphoma
National Taiwan University HospitalP2CCC (48)
Epcoritamab
Lymphoma
Memorial Sloan Kettering Cancer CenterP2CCC (48)
Fludeoxyglucose
Lymphoma
Rigshospitalet, DenmarkP2CCC (48)
Golidocitinib
Lymphoma
Fudan UniversityP1/2CCC (48)
Immunoglobulin G1-Lambda2, Anti-(Severe Acute Respiratory Syndrome (Human) Coronavirus 2 (Sars-Cov-2) Spike (S) Glycoprotein, Receptor Binding Domain (Rbd)), Homo Sapiens Monoclonal Antibod
Lymphoma
Imperial College Healthcare NHS TrustP2CCC (48)
Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3)] And Anti-[Homo Sapiens Cd274 (Programmed Cell Death 1 Ligand 1, Pdl1, Pd-L1, B7 Homolog 1, B7H1, B7-H1, Pdcd1Lg1)], Humanized Monoclonal Antibody, Bispecific, Bivalent
Lymphoma
Mabwell (Shanghai) Bioscience Co., Ltd.P2CCC (48)
Linperlisib
Lymphoma
The First Hospital of Jilin UniversityP1/2CCC (48)
Mecapegfilgrastim
Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaP2CCC (48)
Mit-001
Lymphoma
MitoImmune TherapeuticsP2CCC (48)
Mogamulizumab
Lymphoma
Memorial Sloan Kettering Cancer CenterP2CCC (48)
Nemtabrutinib
Lymphoma
City of Hope Medical CenterP2CCC (48)
Ogalvibart
Lymphoma
Imperial College Healthcare NHS TrustP2CCC (48)
Ptcy
Lymphoma
Center for International Blood and Marrow Transplant ResearchP2CCC (48)
Ruxolitinib
Lymphoma
Center for International Blood and Marrow Transplant ResearchP2CCC (48)
Sonrotoclax
Lymphoma
Christine RyanP2CCC (48)
Sotagliflozin
Lymphoma
Icahn School of Medicine at Mount SinaiP2CCC (48)
Sovleplenib
Lymphoma
HutchmedP1CCC (48)
Synthetic Mva-Based Sars-Cov-2 Vaccine Geo-Cm04S1
Lymphoma
GeoVax, Inc.P2CCC (48)
Tafasitamab
Lymphoma
Brown UniversityP2CCC (48)
Tislezumab
Lymphoma
Fudan UniversityP1/2CCC (48)
tqb2618
Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P1/2CCC (48)
vi-0609
Lymphoma
VIVUS LLCP2CCC (48)
Devimistat
Lymphoma
Memorial Sloan Kettering Cancer CenterP2CC (47)
kt-253
Lymphoma
Kymera Therapeutics, Inc.P1CC (47)
Loncastuximab Tesirine
Lymphoma
Istituto Clinico HumanitasP2CC (47)
Acalabrutinib
Lymphoma
Inhye AhnP1/2CC (46)
Anti-Cd30-Car-Transduced T Cells
Lymphoma
Affiliated Hospital of Nantong UniversityP1/2CC (46)
ARG
Lymphoma
ITM Solucin GmbHP1/2CC (46)
cd70-targeting car-t cells
Lymphoma
St. Jude Children's Research HospitalP1/2CC (46)
Pyruvate
Lymphoma
Rigshospitalet, DenmarkP2CC (45)
Cbl-0137 Free Base
Lymphoma
Children's Oncology GroupP1/2CC (44)
Surufatinib
Lymphoma
HutchmedP1/2CC (44)
xnw5004
Lymphoma
Evopoint Biosciences Inc.P1/2CC (44)
AN4005
Lymphoma
Adlai Nortye Biopharma Co., Ltd.P1CC (43)
aur108
Lymphoma
Aurigene Discovery Technologies LimitedP1CC (43)
aur112
Lymphoma
Aurigene Discovery Technologies LimitedP1CC (43)
Baff Car-T
Lymphoma
Paolo Caimi, MDP1CC (43)
cs5001
Lymphoma
CStone PharmaceuticalsP1CC (43)
f527
Lymphoma
Shandong New Time Pharmaceutical Co., LTDP1CC (43)
gb5005 cart
Lymphoma
The First Affiliated Hospital of Xiamen UniversityP1CC (43)
hdm2005
Lymphoma
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.P1CC (43)
Showing 151 to 200 of 288 assets
PreviousPage 4 of 6Next